Cargando…

Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions

Three therapeutic alternatives for prevention of stroke in patients with atrial fibrillation are available in dabigatran (an oral direct thrombin inhibitor), rivaroxaban, and apixaban (both oral blood coagulation factor Xa inhibitors). Compared with warfarin, these new agents have a more predictable...

Descripción completa

Detalles Bibliográficos
Autor principal: Kalus, James S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884849/
https://www.ncbi.nlm.nih.gov/pubmed/24432039
http://dx.doi.org/10.7573/dic.212251
_version_ 1782298657795604480
author Kalus, James S
author_facet Kalus, James S
author_sort Kalus, James S
collection PubMed
description Three therapeutic alternatives for prevention of stroke in patients with atrial fibrillation are available in dabigatran (an oral direct thrombin inhibitor), rivaroxaban, and apixaban (both oral blood coagulation factor Xa inhibitors). Compared with warfarin, these new agents have a more predictable pharmacodynamic response and fewer major clinically relevant drug–drug interactions. These agents also have few, if any, food–drug interactions, and infrequent or no need for routine laboratory monitoring. These agents also bring new disadvantages, particularly lack of clearly defined reversal strategies, inability to effectively monitor patient response, and higher cost. Selection of the most appropriate oral antithrombotic agent for a given patient is dependent on clinician knowledge of the similarities and critical differences between the available antithrombotic medications.
format Online
Article
Text
id pubmed-3884849
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Just Medical Media Limited
record_format MEDLINE/PubMed
spelling pubmed-38848492014-01-15 Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions Kalus, James S Drugs Context Opinion Three therapeutic alternatives for prevention of stroke in patients with atrial fibrillation are available in dabigatran (an oral direct thrombin inhibitor), rivaroxaban, and apixaban (both oral blood coagulation factor Xa inhibitors). Compared with warfarin, these new agents have a more predictable pharmacodynamic response and fewer major clinically relevant drug–drug interactions. These agents also have few, if any, food–drug interactions, and infrequent or no need for routine laboratory monitoring. These agents also bring new disadvantages, particularly lack of clearly defined reversal strategies, inability to effectively monitor patient response, and higher cost. Selection of the most appropriate oral antithrombotic agent for a given patient is dependent on clinician knowledge of the similarities and critical differences between the available antithrombotic medications. Just Medical Media Limited 2013-04-16 /pmc/articles/PMC3884849/ /pubmed/24432039 http://dx.doi.org/10.7573/dic.212251 Text en © 2013 Kalus JS. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC-ND 3.0) which allows unrestricted sharing, copying and distribution for personal use provided it is properly attributed. Commercial use is not permitted.
spellingShingle Opinion
Kalus, James S
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title_full Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title_fullStr Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title_full_unstemmed Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title_short Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
title_sort antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884849/
https://www.ncbi.nlm.nih.gov/pubmed/24432039
http://dx.doi.org/10.7573/dic.212251
work_keys_str_mv AT kalusjamess antithromboticalternativesforstrokepreventioninatrialfibrillationcriticaldifferencesandremainingquestions